XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia. (PubMed, J Clin Invest) - Sep 2, 2026 - P1 | "XY0206 is a structurally optimized derivative of sunitinib, an inhibitor approved for multiple solid tumors...In primary AML blasts and xenograft models, XY0206 exhibited enhanced antileukemic activity with favorable tolerability relative to gilteritinib...Three of eight patients with prior FLT3 inhibitor-exposed R/R AML also achieved CRc. Together, these findings support further clinical evaluation of XY0206 as a FLT3-directed therapeutic in AML, particularly in disease settings with reduced sensitivity to existing FLT3 inhibitors."
Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • FLT3 • STAT5 • STAT5AWqe
|
|
Bo Jiang; Chao Huang; Chenghua Xu; Dong Zhang; Hong Wang; Jinting Fan; Junyuan Qi; Lichun Kang; Lin Song; Long Shen; Mingming Niu; Mingyuan Sun; Ning Wang; Simeng Li; Siyi Liu; Tao Cheng; Xianfeng Shao; Xiaoxiao Duan; Yajun Jiang; Yang Yang; Youyang Fang
|